Picture of ECO Animal Health logo

EAH ECO Animal Health News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSuper Stock

REG - Eco Animal Health Gp - Appointment of Joint Broker

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250901:nRSA2908Xa&default-theme=true

RNS Number : 2908X  Eco Animal Health Group PLC  01 September 2025

1 September 2025

ECO Animal Health Group plc
(''ECO" or the "Company")

Appointment of Joint Broker

 

ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health
company with a portfolio of marketed veterinary products and a maturing
proprietary R&D pipeline, announces the appointment of Panmure Liberum
Limited ("Panmure Liberum") as Joint Broker to the Company with immediate
effect. Singer Capital Markets will remain as the Company's Nominated Adviser
and Joint Broker.

 

-Ends-

 

Contacts

                                                                020 8447 8899

 ECO Animal Health Group plc

 David Hallas (Chief Executive Officer)

 Christopher Wilks (Chief Financial Officer)

 ICR Healthcare (Financial PR)                                  020 3709 5700

 Mary-Jane Elliott

 Jessica Hodgson

 Singer Capital Markets (Nominated Adviser & Joint Broker)      020 7496 3000

 Philip Davies

 Sam Butcher

 Panmure Liberum (Joint Broker)                                 020 3100 2000

 Emma Earl

 Will Goode

 Mark Rogers

 Rupert Dearden

 Equity Development                                             020 7065 2692

 Hannah Crowe

 Matt Evans

 

About ECO Animal Health

ECO Animal Health is a world leader in animal health, developing and marketing
branded veterinary pharmaceuticals globally, with expertise in antibiotics and
vaccines for pigs and poultry. We have a maturing proprietary R&D
pipeline.

 

Headquartered in the UK, with global offices including R&D and
manufacturing, we have marketing authorisations in over 70 countries and
employ over 200 people worldwide.

 

Our lead product, Aivlosin(®) is a proprietary, patented medication which is
effective against both respiratory and intestinal diseases in pigs and
poultry.

 

Click here for more information: https://ecoanimalhealth.com
(https://ecoanimalhealth.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPZZGZRZLKGKZM

Recent news on ECO Animal Health

See all news